|
1
|
Singer M, Deutschman CS, Seymour CW,
Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche
JD, Coopersmith CM, et al: The third international consensus
definitions for sepsis and septic shock (sepsis-3). JAMA.
315:801–810. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bone RC, Balk RA, Cerra FB, Dellinger RP,
Fein AM, Knaus WA, Schein RM and Sibbald WJ: Definitions for sepsis
and organ failure and guidelines for the use of innovative
therapies in sepsis. The ACCP/SCCM consensus conference committee.
American college of chest physicians/society of critical care
medicine. Chest. 101:1644–1655. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cecconi M, Evans L, Levy M and Rhodes A:
Sepsis and septic shock. Lancet. 392:75–87. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gheen N: Sepsis-3 definitions. Ann Emerg
Med. 68:784–785. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gong T, Fu Y, Wang Q, Loughran PA, Li Y,
Billiar TR, Wen Z, Liu Y and Fan J: Decoding the multiple functions
of ZBP1 in the mechanism of sepsis-induced acute lung injury.
Commun Biol. 7:13612024. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li Y, Hu C, Zhai P, Zhang J, Jiang J, Suo
J, Hu B, Wang J, Weng X, Zhou X, et al: Fibroblastic reticular
cell-derived exosomes are a promising therapeutic approach for
septic acute kidney injury. Kidney Int. 105:508–523. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Song YQ, Lin WJ, Hu HJ, Wu SH, Jing L, Lu
Q and Zhu W: Sodium tanshinone IIA sulfonate attenuates
sepsis-associated brain injury via inhibiting NOD-like receptor
3/caspase-1/gasdermin D-mediated pyroptosis. Int Immunopharmacol.
118:1101112023. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xu JQ, Zhang WY, Fu JJ, Fang XZ, Gao CG,
Li C, Yao L, Li QL, Yang XB, Ren LH, et al: Viral sepsis:
Diagnosis, clinical features, pathogenesis, and clinical
considerations. Mil Med Res. 11:782024.PubMed/NCBI
|
|
9
|
Werdan K, Schmidt H, Ebelt H, Zorn-Pauly
K, Koidl B, Hoke RS, Heinroth K and Müller-Werdan U: Impaired
regulation of cardiac function in sepsis, SIRS, and MODS. Can J
Physiol Pharmacol. 87:266–274. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hasegawa D, Ishisaka Y, Maeda T,
Prasitlumkum N, Nishida K, Dugar S and Sato R: Prevalence and
prognosis of sepsis-induced cardiomyopathy: A systematic review and
meta-analysis. J Intensive Care Med. 38:797–808. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Antonucci E, Fiaccadori E, Donadello K,
Taccone FS, Franchi F and Scolletta S: Myocardial depression in
sepsis: From pathogenesis to clinical manifestations and treatment.
J Crit Care. 29:500–511. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Parker MM, Shelhamer JH, Bacharach SL,
Green MV, Natanson C, Frederick TM, Damske BA and Parrillo JE:
Profound but reversible myocardial depression in patients with
septic shock. Ann Intern Med. 100:483–490. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
MacLean LD, Mulligan WG, McLean AP and
Duff JH: Patterns of septic shock in man-a detailed study of 56
patients. Ann Surg. 166:543–562. 1967. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Parrillo JE: Pathogenetic mechanisms of
septic shock. N Engl J Med. 328:1471–1477. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Abraham E and Singer M: Mechanisms of
sepsis-induced organ dysfunction. Crit Care Med. 35:2408–2416.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Levy RJ and Deutschman CS: Cytochrome c
oxidase dysfunction in sepsis. Crit Care Med. 35 (9
Suppl):S468–S475. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mebazaa A, De Keulenaer GW, Paqueron X,
Andries LJ, Ratajczak P, Lanone S, Frelin C, Longrois D, Payen D,
Brutsaert DL and Sys SU: Activation of cardiac endothelium as a
compensatory component in endotoxin-induced cardiomyopathy: role of
endothelin, prostaglandins, and nitric oxide. Circulation.
104:3137–3144. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hobai IA, Edgecomb J, LaBarge K and
Colucci WS: Dysregulation of intracellular calcium transporters in
animal models of sepsis-induced cardiomyopathy. Shock. 43:3–15.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Miranda M, Balarini M, Caixeta D and
Bouskela E: Microcirculatory dysfunction in sepsis:
Pathophysiology, clinical monitoring, and potential therapies. Am J
Physiol Heart Circ Physiol. 311:H24–H35. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Henedak NT, El-Abhar HS, Soubh AA and
Abdallah DM: NLRP3 Inflammasome: A central player in renal
pathologies and nephropathy. Life Sci. 351:1228132024. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tao S, Fan W, Liu J, Wang T, Zheng H, Qi
G, Chen Y, Zhang H, Guo Z and Zhou F: NLRP3 inflammasome: An
Emerging therapeutic target for Alzheimer's disease. J Alzheimers
Dis. 96:1383–1398. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tengesdal IW, Dinarello CA and Marchetti
C: NLRP3 and cancer: Pathogenesis and therapeutic opportunities.
Pharmacol Ther. 251:1085452023. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sayaf K, Battistella S and Russo FP: NLRP3
inflammasome in acute and chronic liver diseases. Int J Mol Sci.
25:45372024. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang Y, You YK, Guo J, Wang J, Shao B, Li
H, Meng X, Lan HY and Chen H: C-reactive protein promotes diabetic
kidney disease via Smad3-mediated NLRP3 inflammasome activation.
Mol Ther. 33:263–278. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wen Y, Liu Y, Liu W, Liu W, Dong J, Liu Q,
Hao H and Ren H: Research progress on the activation mechanism of
NLRP3 inflammasome in septic cardiomyopathy. Immun Inflamm Dis.
11:e10392023. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Toldo S and Abbate A: The role of the
NLRP3 inflammasome and pyroptosis in cardiovascular diseases. Nat
Rev Cardiol. 21:219–237. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhu W, Bao X, Yang Y, Xing M, Xiong S,
Chen S, Zhong Y, Hu X, Lu Q, Wang K, et al: Peripheral evolution of
tanshinone IIA and cryptotanshinone for discovery of a potent and
specific NLRP3 inflammasome inhibitor. J Med Chem. 68:3460–3479.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zheng Y, Zhang X, Wang Z, Zhang R, Wei H,
Yan X, Jiang X and Yang L: MCC950 as a promising candidate for
blocking NLRP3 inflammasome activation: A review of preclinical
research and future directions. Arch Pharm (Weinheim).
357:e24004592024. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li H, Guan Y, Liang B, Ding P, Hou X, Wei
W and Ma Y: Therapeutic potential of MCC950, a specific inhibitor
of NLRP3 inflammasome. Eur J Pharmacol. 928:1750912022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cabral JE, Wu A, Zhou H, Pham MA, Lin S
and McNulty R: Targeting the NLRP3 inflammasome for inflammatory
disease therapy. Trends Pharmacol Sci. 46:503–519. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Takeuchi O and Akira S: Pattern
recognition receptors and inflammation. Cell. 140:805–820. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen Y, Ye X, Escames G, Lei W, Zhang X,
Li M, Jing T, Yao Y, Qiu Z, Wang Z, et al: The NLRP3 inflammasome:
Contributions to inflammation-related diseases. Cell Mol Biol Lett.
28:512023. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fu J and Wu H: Structural mechanisms of
NLRP3 inflammasome assembly and activation. Annu Rev Immunol.
41:301–316. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yu X, Matico RE, Miller R, Chauhan D, Van
Schoubroeck B, Grauwen K, Suarez J, Pietrak B, Haloi N, Yin Y, et
al: Structural basis for the oligomerization-facilitated NLRP3
activation. Nat Commun. 15:11642024. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jo EK, Kim JK, Shin DM and Sasakawa C:
Molecular mechanisms regulating NLRP3 inflammasome activation. Cell
Mol Immunol. 13:148–159. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Martínez-García JJ, Martínez-Banaclocha H,
Angosto-Bazarra D, de Torre-Minguela C, Baroja-Mazo A, Alarcón-Vila
C, Martínez-Alarcón L, Amores-Iniesta J, Martín-Sánchez F, Ercole
GA, et al: P2X7 receptor induces mitochondrial failure in monocytes
and compromises NLRP3 inflammasome activation during sepsis. Nat
Commun. 10:27112019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wu QR, Yang H, Zhang HD, Cai YJ, Zheng YX,
Fang H, Wang ZF, Kuang SJ, Rao F, Huang HL, et al: IP3R2-mediated
Ca2+ release promotes LPS-induced cardiomyocyte
pyroptosis via the activation of NLRP3/Caspase-1/GSDMD pathway.
Cell Death Discov. 10:912024. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zeng Y, Cao G, Lin L, Zhang Y, Luo X, Ma
X, Aiyisake A and Cheng Q: Resveratrol attenuates sepsis-induced
cardiomyopathy in rats through anti-ferroptosis via the Sirt1/Nrf2
pathway. J Invest Surg. 36:21575212023. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Liu S, Bi Y, Han T, Li YE, Wang Q, Wu NN,
Xu C, Ge J, Hu R and Zhang Y: The E3 ubiquitin ligase MARCH2
protects against myocardial ischemia-reperfusion injury through
inhibiting pyroptosis via negative regulation of PGAM5/MAVS/NLRP3
axis. Cell Discov. 10:242024. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Karasawa T and Takahashi M: The
crystal-induced activation of NLRP3 inflammasomes in
atherosclerosis. Inflamm Regen. 37:182017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ye T, Wang C, Yan J, Qin Z, Qin W, Ma Y,
Wan Q, Lu W, Zhang M, Tay FR, et al: Lysosomal destabilization: A
missing link between pathological calcification and osteoarthritis.
Bioact Mater. 34:37–50. 2023.PubMed/NCBI
|
|
42
|
Du G, Healy LB, David L, Walker C, El-Baba
TJ, Lutomski CA, Goh B, Gu B, Pi X, Devant P, et al: ROS-dependent
S-palmitoylation activates cleaved and intact gasdermin D. Nature.
630:437–446. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Huang Y, Xu W and Zhou R: NLRP3
inflammasome activation and cell death. Cell Mol Immunol.
18:2114–2127. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Saller BS, Wöhrle S, Fischer L, Dufossez
C, Ingerl IL, Kessler S, Mateo-Tortola M, Gorka O, Lange F, Cheng
Y, et al: Acute suppression of mitochondrial ATP production
prevents apoptosis and provides an essential signal for NLRP3
inflammasome activation. Immunity. 58:90–107.e11. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ting JP, Lovering RC, Alnemri ES, Bertin
J, Boss JM, Davis BK, Flavell RA, Girardin SE, Godzik A, Harton JA,
et al: The NLR gene family: A standard nomenclature. Immunity.
28:285–287. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhu Y, Zhang H, Mao H, Zhong S, Huang Y,
Chen S, Yan K, Zhao Z, Hao X, Zhang Y, et al: FAAH served a key
membrane-anchoring and stabilizing role for NLRP3 protein
independently of the endocannabinoid system. Cell Death Differ.
30:168–183. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yu S, Fu J, Wang J, Zhao Y, Liu B, Wei J,
Yan X and Su J: The influence of mitochondrial-DNA-driven
inflammation pathways on macrophage polarization: A new perspective
for targeted immunometabolic therapy in cerebral
ischemia-reperfusion injury. Int J Mol Sci. 23:1352021. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zheng X, Zhong T, Ma Y, Wan X, Qin A, Yao
B, Zou H, Song Y and Yin D: Bnip3 mediates doxorubicin-induced
cardiomyocyte pyroptosis via caspase-3/GSDME. Life Sci.
242:1171862020. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Rodrigue-Gervais IG and Saleh M: Caspases
and immunity in a deadly grip. Trends Immunol. 34:41–49. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Miao R, Jiang C, Chang WY, Zhang H, An J,
Ho F, Chen P, Zhang H, Junqueira C, Amgalan D, et al: Gasdermin D
permeabilization of mitochondrial inner and outer membranes
accelerates and enhances pyroptosis. Immunity. 56:2523–2541.e8.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Gritte RB, Souza-Siqueira T, Borges da
Silva E, Dos Santos de Oliveira LC, Cerqueira Borges R, Alves HHO,
Masi LN, Murata GM, Gorjão R, Levada-Pires AC, et al: Evidence for
monocyte reprogramming in a long-term postsepsis study. Crit Care
Explor. 4:e07342022.PubMed/NCBI
|
|
52
|
Jin Y, Fleishman JS, Ma Y, Jing X, Guo Q,
Shang W and Wang H: NLRP3 inflammasome targeting offers a novel
therapeutic paradigm for sepsis-induced myocardial injury. Drug Des
Devel Ther. 19:1025–1041. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Shen J, Wu JM, Hu GM, Li MZ, Cong WW, Feng
YN, Wang SX, Li ZJ, Xu M, Dong ED, et al: Membrane nanotubes
facilitate the propagation of inflammatory injury in the heart upon
overactivation of the β-adrenergic receptor. Cell Death Dis.
11:9582020. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Wiersinga WJ, Leopold SJ, Cranendonk DR
and van der Poll T: Host innate immune responses to sepsis.
Virulence. 5:36–44. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Fajgenbaum DC and June CH: Cytokine storm.
N Engl J Med. 383:2255–2273. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Blevins HM, Xu Y, Biby S and Zhang S: The
NLRP3 inflammasome pathway: A review of mechanisms and inhibitors
for the treatment of inflammatory diseases. Front Aging Neurosci.
14:8790212022. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Napodano C, Carnazzo V, Basile V, Pocino
K, Stefanile A, Gallucci S, Natali P, Basile U and Marino M: NLRP3
inflammasome involvement in heart, liver, and lung diseases-A
lesson from cytokine storm syndrome. Int J Mol Sci. 24:165562023.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Fujimura K, Karasawa T, Komada T, Yamada
N, Mizushina Y, Baatarjav C, Matsumura T, Otsu K, Takeda N,
Mizukami H, et al: NLRP3 inflammasome-driven IL-1β and IL-18
contribute to lipopolysaccharide-induced septic cardiomyopathy. J
Mol Cell Cardiol. 180:58–68. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Sun J, Ge X, Wang Y, Niu L, Tang L and Pan
S: USF2 knockdown downregulates THBS1 to inhibit the TGF-β
signaling pathway and reduce pyroptosis in sepsis-induced acute
kidney injury. Pharmacol Res. 176:1059622022. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Xie Y, Li X, Deng W, Nan N, Zou H, Gong L,
Chen M, Yu J, Chen P, Cui D and Zhang F: Knockdown of USF2 inhibits
pyroptosis of podocytes and attenuates kidney injury in lupus
nephritis. J Mol Histol. 54:313–327. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Dong W, Liao R, Weng J, Du X, Chen J, Fang
X, Liu W, Long T, You J, Wang W and Peng X: USF2 activates
RhoB/ROCK pathway by transcriptional inhibition of miR-206 to
promote pyroptosis in septic cardiomyocytes. Mol Cell Biochem.
479:1093–1108. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Zhang Y, Li S, Fan X and Wu Y:
Pretreatment with indole-3-propionic acid attenuates
lipopolysaccharide-induced cardiac dysfunction and inflammation
through the AhR/NF-κB/NLRP3 pathway. J Inflamm Res. 17:5293–5309.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Konvalinka A: myo-Inositol oxygenase: A
novel kidney-specific biomarker of acute kidney injury? Clin Chem.
60:708–710. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Wang Y, Lu J, Lin B, Chen J, Lin F, Zheng
Q, Xue X, Wei Y, Chen S and Xu N: Integrated analysis of MIOX gene
in prognosis of clear-cell renal cell carcinoma. Cell Death Dis.
16:3682025. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Zhou W, Yu C and Long Y: Myo-inositol
oxygenase (MIOX) accelerated inflammation in the model of
infection-induced cardiac dysfunction by NLRP3 inflammasome. Immun
Inflamm Dis. 11:e8292023. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Vitale I, Pietrocola F, Guilbaud E,
Aaronson SA, Abrams JM, Adam D, Agostini M, Agostinis P, Alnemri
ES, Altucci L, et al: Apoptotic cell death in disease-current
understanding of the NCCD 2023. Cell Death Differ. 30:1097–1154.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Fu Y, Zhang HJ, Zhou W, Lai ZQ and Dong
YF: The protective effects of sophocarpine on sepsis-induced
cardiomyopathy. Eur J Pharmacol. 950:1757452023. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Mahidhara R and Billiar TR: Apoptosis in
sepsis. Crit Care Med. 28 (4 Suppl):N105–N113. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Maluleke TT, Manilall A, Shezi N, Baijnath
S and Millen AME: Acute exposure to LPS induces cardiac dysfunction
via the activation of the NLRP3 inflammasome. Sci Rep.
14:243782024. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Speir M and Lawlor KE: RIP-roaring
inflammation: RIPK1 and RIPK3 driven NLRP3 inflammasome activation
and autoinflammatory disease. Semin Cell Dev Biol. 109:114–124.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Zhou Y, Chai Z, Pandeya A, Yang L, Zhang
Y, Zhang G, Wu C, Li Z and Wei Y: Caspase-11 and NLRP3 exacerbate
systemic Klebsiella infection through reducing mitochondrial ROS
production. Front Immunol. 16:15161202025. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Yang Y, Lei W, Qian L, Zhang S, Yang W, Lu
C, Song Y, Liang Z, Deng C, Chen Y, et al: Activation of NR1H3
signaling pathways by psoralidin attenuates septic myocardial
injury. Free Radic Biol Med. 204:8–19. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Qu M, Wang Y, Qiu Z, Zhu S, Guo K, Chen W,
Miao C and Zhang H: Necroptosis, pyroptosis, ferroptosis in sepsis
and treatment. Shock. 57:161–171. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Li N, Zhou H, Wu H, Wu Q, Duan M, Deng W
and Tang Q: STING-IRF3 contributes to lipopolysaccharide-induced
cardiac dysfunction, inflammation, apoptosis and pyroptosis by
activating NLRP3. Redox Biol. 24:1012152019. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Wang D, Lin Z, Zhou Y, Su M, Zhang H, Yu L
and Li M: Atractylenolide I ameliorates sepsis-induced
cardiomyocyte injury by inhibiting macrophage polarization through
the modulation of the PARP1/NLRP3 signaling pathway. Tissue Cell.
89:1024242024. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Deng C, Liu Q, Zhao H, Qian L, Lei W, Yang
W, Liang Z, Tian Y, Zhang S, Wang C, et al: Activation of NR1H3
attenuates the severity of septic myocardial injury by inhibiting
NLRP3 inflammasome. Bioeng Transl Med. 8:e105172023. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
D'Souza CA and Heitman J: Dismantling the
cryptococcus coat. Trends Microbiol. 9:112–113. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Yu P, Zhang X, Liu N, Tang L, Peng C and
Chen X: Pyroptosis: Mechanisms and diseases. Signal Transduct
Target Ther. 6:1282021. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Zheng X, Chen W, Gong F, Chen Y and Chen
E: The role and mechanism of pyroptosis and potential therapeutic
targets in sepsis: A review. Front Immunol. 12:7119392021.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Coll RC, Schroder K and Pelegrín P: NLRP3
and pyroptosis blockers for treating inflammatory diseases. Trends
Pharmacol Sci. 43:653–668. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Yarovinsky TO, Su M, Chen C, Xiang Y, Tang
WH and Hwa J: Pyroptosis in cardiovascular diseases: Pumping
gasdermin on the fire. Semin Immunol. 69:1018092023. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Fan Y, Guan B, Xu J, Zhang H, Yi L and
Yang Z: Role of toll-like receptor-mediated pyroptosis in
sepsis-induced cardiomyopathy. Biomed Pharmacother. 167:1154932023.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Song C, Zhang Y, Pei Q, Zheng L, Wang M,
Shi Y, Wu S, Ni W, Fu X, Peng Y, et al: HSP70 alleviates
sepsis-induced cardiomyopathy by attenuating mitochondrial
dysfunction-initiated NLRP3 inflammasome-mediated pyroptosis in
cardiomyocytes. Burns Trauma. 10:tkac0432022. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Cao Z, Li W, Shao Z, Liu X, Zeng Y, Lin P,
Lin C, Zhao Y, Li T, Zhao Z, et al: Apelin ameliorates
sepsis-induced myocardial dysfunction via inhibition of
NLRP3-mediated pyroptosis of cardiomyocytes. Heliyon.
10:e245682024. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Duan F, Li L, Liu S, Tao J, Gu Y, Li H, Yi
X, Gong J, You D, Feng Z, et al: Cortistatin protects against
septic cardiomyopathy by inhibiting cardiomyocyte pyroptosis
through the SSTR2-AMPK-NLRP3 pathway. Int Immunopharmacol.
134:1121862024. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Lu C, Liu J, Escames G, Yang Y, Wu X, Liu
Q, Chen J, Song Y, Wang Z, Deng C, et al: PIK3CG regulates
NLRP3/GSDMD-mediated pyroptosis in septic myocardial injury.
Inflammation. 46:2416–2432. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Liu Q, Dong Y, Escames G, Wu X, Ren J,
Yang W, Zhang S, Zhu Y, Tian Y, Acuña-Castroviejo D and Yang Y:
Identification of PIK3CG as a hub in septic myocardial injury using
network pharmacology and weighted gene co-expression network
analysis. Bioeng Transl Med. 8:e103842022. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Liu S, Yao S, Yang H, Liu S and Wang Y:
Autophagy: Regulator of cell death. Cell Death Dis. 14:6482023.
View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Ren C, Zhang H, Wu TT and Yao YM:
Autophagy: A potential therapeutic target for reversing
sepsis-induced immunosuppression. Front Immunol. 8:18322017.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Wang S, Long H, Hou L, Feng B, Ma Z, Wu Y,
Zeng Y, Cai J, Zhang DW and Zhao G: The mitophagy pathway and its
implications in human diseases. Signal Transduct Target Ther.
8:3042023. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Shan X, Tao W, Li J, Tao W, Li D, Zhou L,
Yang X, Dong C, Huang S, Chu X and Zhang C: Kai-Xin-San ameliorates
Alzheimer's disease-related neuropathology and cognitive impairment
in APP/PS1 mice via the mitochondrial autophagy-NLRP3 inflammasome
pathway. J Ethnopharmacol. 329:1181452024. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Lei X, Wang J, Zhang F, Tang X, He F,
Cheng S, Zou F and Yan W: Micheliolide ameliorates
lipopolysaccharide-induced acute kidney injury through suppression
of NLRP3 activation by promoting mitophagy via Nrf2/PINK1/Parkin
axis. Int Immunopharmacol. 138:1125272024. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Zhou F, Lian W, Yuan X, Wang Z, Xia C, Yan
Y, Wang W, Tong Z, Cheng Y, Xu J, et al: Cornuside alleviates
cognitive impairments induced by Aβ1-42 through
attenuating NLRP3-mediated neurotoxicity by promoting mitophagy.
Alzheimers Res Ther. 17:472025. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Ajoolabady A, Chiong M, Lavandero S,
Klionsky DJ and Ren J: Mitophagy in cardiovascular diseases:
Molecular mechanisms, pathogenesis, and treatment. Trends Mol Med.
28:836–849. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Zhu L, Wang Z, Sun X, Yu J, Li T, Zhao H,
Ji Y, Peng B and Du M: STAT3/Mitophagy axis coordinates macrophage
NLRP3 inflammasome activation and inflammatory bone loss. J Bone
Miner Res. 38:335–353. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Luo L, Wang F, Xu X, Ma M, Kuang G, Zhang
Y, Wang D, Li W, Zhang N and Zhao K: STAT3 promotes NLRP3
inflammasome activation by mediating NLRP3 mitochondrial
translocation. Exp Mol Med. 56:1980–1990. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Nedel W, Deutschendorf C and Portela LVC:
Sepsis-induced mitochondrial dysfunction: A narrative review. World
J Crit Care Med. 12:139–152. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Jing J, Yang F, Wang K, Cui M, Kong N,
Wang S, Qiao X, Kong F, Zhao D, Ji J, et al: UFMylation of NLRP3
prevents its autophagic degradation and facilitates inflammasome
activation. Adv Sci (Weinh). 12:e24067862025. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Yang S, Huang G and Ting JP: Mitochondria
and NLRP3: To die or inflame. Immunity. 58:5–7. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Meyers AK, Wang Z, Han W, Zhao Q, Zabalawi
M, Duan L, Liu J, Zhang Q, Manne RK, Lorenzo F, et al: Pyruvate
dehydrogenase kinase supports macrophage NLRP3 inflammasome
activation during acute inflammation. Cell Rep. 42:1119412023.
View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Thorburn J, Xu S and Thorburn A: MAP
kinase- and Rho-dependent signals interact to regulate gene
expression but not actin morphology in cardiac muscle cells. EMBO
J. 16:1888–1900. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Tan Y, Zhang Y, He J, Wu F, Wu D, Shi N,
Liu W, Li Z, Liu W, Zhou H and Chen W: Dual specificity phosphatase
1 attenuates inflammation-induced cardiomyopathy by improving
mitophagy and mitochondrial metabolism. Mol Metab. 64:1015672022.
View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Li FJ, Hu H, Wu L, Luo B, Zhou Y, Ren J,
Lin J, Reiter RJ, Wang S, Dong M, et al: Ablation of mitophagy
receptor FUNDC1 accentuates septic cardiomyopathy through
ACSL4-dependent regulation of ferroptosis and mitochondrial
integrity. Free Radic Biol Med. 225:75–86. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Nie J and Qiu H: DUSP1 mitigates
MSU-induced immune response in gouty arthritis reinforcing
autophagy. Front Biosci (Landmark Ed). 29:2222024. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Jiang H, Chen F, Song D, Zhou X, Ren L and
Zeng M: Dynamin-related protein 1 is involved in mitochondrial
damage, defective mitophagy, and NLRP3 inflammasome activation
induced by MSU crystals. Oxid Med Cell Longev. 2022:50644942022.
View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Chen S, Ma J, Yin P and Liang F: The
landscape of mitophagy in sepsis reveals PHB1 as an NLRP3
inflammasome inhibitor. Front Immunol. 14:11884822023. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Song D, Tao W, Liu F, Wu X, Bi H, Shu J,
Wang D and Li X: Lipopolysaccharide promotes NLRP3 inflammasome
activation by inhibiting TFEB-mediated autophagy in NRK-52E cells.
Mol Immunol. 163:127–135. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Zhang R, Guan S, Meng Z, Zhang D and Lu J:
Ginsenoside Rb1 alleviates 3-MCPD-induced renal cell pyroptosis by
activating mitophagy. Food Chem Toxicol. 186:1145222024. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Hu D, Sheeja Prabhakaran H, Zhang YY, Luo
G, He W and Liou YC: Mitochondrial dysfunction in sepsis:
Mechanisms and therapeutic perspectives. Crit Care. 28:2922024.
View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Silva RCMC: Mitochondria, autophagy and
inflammation: Interconnected in aging. Cell Biochem Biophys.
82:411–426. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Miaczynska M, Christoforidis S, Giner A,
Shevchenko A, Uttenweiler-Joseph S, Habermann B, Wilm M, Parton RG
and Zerial M: APPL proteins link Rab5 to nuclear signal
transduction via an endosomal compartment. Cell. 116:445–456. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Wu KKL and Cheng KKY: A new role of the
early endosome in restricting NLRP3 inflammasome via mitophagy.
Autophagy. 18:1475–1477. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Yu WM, Appler JM, Kim YH, Nishitani AM,
Holt JR and Goodrich LV: A Gata3-Mafb transcriptional network
directs post-synaptic differentiation in synapses specialized for
hearing. Elife. 2:e013412013. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Cui H, Banerjee S, Xie N, Dey T, Liu RM,
Sanders YY and Liu G: MafB regulates NLRP3 inflammasome activation
by sustaining p62 expression in macrophages. Commun Biol.
6:10472023. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Wang J, Wu M, Magupalli VG, Dahlberg PD,
Wu H and Jensen GJ: Human NLRP3 inflammasome activation leads to
formation of condensate at the microtubule organizing center.
bioRxiv [Preprint]. 2024.09.12.612739. 2024.
|
|
116
|
Chen X, Yuan T, Zheng D, Li F, Xu H, Ye M,
Liu S and Li J: Cardiomyocyte mitochondrial mono-ADP-ribosylation
dictates cardiac tolerance to sepsis by configuring bioenergetic
reserve in male mice. Nat Commun. 16:81192025. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Wan C and Wang Y: Integrated multi-omics
of mitophagy-related molecular subtype characterization and
biomarker identification in sepsis. Sci Rep. 16:7012025. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Mohd S, Sharma V, Harish V, Kumar R and
Pilli G: Exploring thiazolidinedione-naphthalene analogues as
potential antidiabetic agents: Design, synthesis, molecular docking
and in-vitro evaluation. Cell Biochem Biophys. 83:2213–2226. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Hu C, He X, Zhang H, Hu X, Liao L, Cai M,
Lin Z, Xiang J, Jia X, Lu G, et al: Tanshinone I limits
inflammasome activation of macrophage via docking into Syk to
alleviate DSS-induced colitis in mice. Mol Immunol. 173:88–98.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Liang D, Tang S, Liu L, Zhao M, Ma X, Zhao
Y, Shen C, Liu Q, Tang J, Zeng J and Chen N: Tanshinone I
attenuates gastric precancerous lesions by inhibiting epithelial
mesenchymal transition through the p38/STAT3 pathway. Int
Immunopharmacol. 124:1109022023. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Zhao J, Liu H, Hong Z, Luo W, Mu W, Hou X,
Xu G, Fang Z, Ren L, Liu T, et al: Tanshinone I specifically
suppresses NLRP3 inflammasome activation by disrupting the
association of NLRP3 and ASC. Mol Med. 29:842023. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Dai Y, Zhang X, Xu Y, Wu Y and Yang L: The
protective effects of cinnamyl alcohol against hepatic steatosis,
oxidative and inflammatory stress in nonalcoholic fatty liver
disease induced by childhood obesity. Immunol Invest. 52:1008–1022.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Yoshizaki K, Frias DP, Maier K, Smelan J,
Correia AT, Oliveira LMDS, Amato-Lourenço LF, Santillo BT, Prado
CM, Oshiro TM, et al: Exposure of cinnamyl alcohol in co-culture of
BEAS-2B and dendritic cells: Interaction between CYP450 and
cytokines. J Appl Toxicol. 44:1317–1328. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Zou L, Li C, Chen X, Yu F, Huang Q, Chen
L, Wu W and Liu Q: The anti-inflammatory effects of cinnamyl
alcohol on sepsis-induced mice via the NLRP3 inflammasome pathway.
Ann Transl Med. 10:482022. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Cheng Z, Huang M, Li W, Hou L, Jin L, Fan
Q, Zhang L, Li C, Zeng L, Yang C, et al: HECTD3 inhibits NLRP3
inflammasome assembly and activation by blocking NLRP3-NEK7
interaction. Cell Death Dis. 15:862024. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Guo J, Miao Y, Nie F, Gao F, Li H, Wang Y,
Liu Q, Zhang T, Yang X, Liu L, et al: Zn-Shik-PEG nanoparticles
alleviate inflammation and multi-organ damage in sepsis. J
Nanobiotechnology. 21:4482023. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Ding Y, Liu L, Wu Y, Wang Y and Zhao R:
Optimization of the transdermal delivery system in astilbin
microemulsion with improved stability and anti-psoriatic activity.
Curr Drug Deliv. 20:281–291. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Li C, Huang Y, Wu C, Qiu Y, Zhang L, Xu J,
Zheng J, Zhang X, Li F and Xia D: Astilbin inhibited neutrophil
extracellular traps in gouty arthritis through suppression of
purinergic P2Y6 receptor. Phytomedicine. 130:1557542024. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Geng X, Fu Z, Geng G, Chi K, Liu C, Hong
H, Cai G, Chen X and Hong Q: Astilbin improves the therapeutic
effects of mesenchymal stem cells in AKI-CKD mice by regulating
macrophage polarization through PTGS2-mediated pathway. Stem Cell
Res Ther. 15:4272024. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Dou JY, Zhou MJ, Xuan MY, Guo J, Liu SH,
Lian LH, Cui ZY, Nan JX and Wu YL: Astilbin alleviates hepatic
fibrosis through PXR-PINK1/Parkin pathway: A new strategy by
regulating hepatic stellate cells-macrophage crosstalk.
Phytomedicine. 135:1561442024. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Yang D and Zhang QF: The natural source,
physicochemical properties, biological activities and metabolism of
astilbin. Crit Rev Food Sci Nutr. 63:9506–9518. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Fang Z, Wang G, Huang R, Liu C,
Yushanjiang F, Mao T and Li J: Astilbin protects from
sepsis-induced cardiac injury through the NRF2/HO-1 and TLR4/NF-κB
pathway. Phytother Res. 38:1044–1058. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Liu YF, Li WQ, Hu ND, Ai B, Xia HX, Guo X,
Chen Z and Xia H: Brevilin A ameliorates sepsis-induced
cardiomyopathy through inhibiting NLRP3 inflammation. Ann Med Surg
(Lond). 85:5952–5962. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Fang H, Wang Y, Deng J, Zhang H, Wu Q, He
L, Xu J, Shao X, Ouyang X, He Z, et al: Sepsis-induced gut
dysbiosis mediates the susceptibility to sepsis-associated
encephalopathy in mice. mSystems. 7:e01399212022. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Zhuang H, Ren X, Jiang F and Zhou P:
Indole-3-propionic acid alleviates chondrocytes inflammation and
osteoarthritis via the AhR/NF-κB axis. Mol Med. 29:172023.
View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Heumel S, de Rezende Rodovalho V, Urien C,
Specque F, Brito Rodrigues P, Robil C, Delval L, Sencio V, Descat
A, Deruyter L, et al: Shotgun metagenomics and systemic targeted
metabolomics highlight indole-3-propionic acid as a protective gut
microbial metabolite against influenza infection. Gut Microbes.
16:23250672024. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Ilha M, Sehgal R, Matilainen J, Rilla K,
Kaminska D, Gandhi S, Männistö V, Ling C, Romeo S, Pajukanta P, et
al: Indole-3-propionic acid promotes hepatic stellate cells
inactivation. J Transl Med. 23:2532025. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Rapti E, Adamantidi T, Efthymiopoulos T,
Kyzas GZ and Tsoupras A: Potential applications of the
anti-inflammatory, antithrombotic and antioxidant health-promoting
properties of curcumin: A critical review. Nutraceuticals.
4:562–595. 2024. View Article : Google Scholar
|
|
139
|
Shi Y, Wu Q, Lu Y, Meng LP, Xu XL, Wang XJ
and Chen W: Arginine-glycine-aspartic acid-anchored curcumin-based
nanotherapeutics inhibit pyroptosis-induced cytokine release
syndrome for in vivo and in vitro sepsis applications. Curr Pharm
Des. 29:283–294. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Karimi A, Pourreza S, Vajdi M, Mahmoodpoor
A, Sanaie S, Karimi M and Tarighat-Esfanjani A: Evaluating the
effects of curcumin nanomicelles on clinical outcome and cellular
immune responses in critically ill sepsis patients: A randomized,
double-blind, and placebo-controlled trial. Front Nutr.
9:10378612022. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Kim D, Kim S, Kang MS, Yin Z and Min B:
Cell type specific IL-27p28 (IL-30) deletion in mice uncovers an
unexpected regulatory function of IL-30 in autoimmune inflammation.
Sci Rep. 13:18122023. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Sung M, Lim S, Park S, Choi Y and Kim S:
Anti-inflammatory effects of phytosphingosine-regulated cytokines
and NF-kB and MAPK mechanism. Cell Mol Biol (Noisy-le-grand).
70:22–30. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Shehata RR, Atta SA, Fatma AS, Aml RA and
Gomaa AS: Association of serum IL-30 and soluble GP130 with the
risk of psoriasis vulgaris. Egypt J Immunol. 31:61–70. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Zhao M, Zheng Z, Zhang P, Xu Y, Zhang J,
Peng S, Liu J, Pan W, Yin Z, Xu S, et al: IL-30 protects against
sepsis-induced myocardial dysfunction by inhibiting
pro-inflammatory macrophage polarization and pyroptosis. iScience.
26:1075442023. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Arruri VK, Gundu C, Kalvala AK, Sherkhane
B, Khatri DK and Singh SB: Carvacrol abates NLRP3 inflammasome
activation by augmenting Keap1/Nrf-2/p62 directed autophagy and
mitochondrial quality control in neuropathic pain. Nutr Neurosci.
25:1731–1746. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Joshi S, Kundu S, Priya VV, Kulhari U,
Mugale MN and Sahu BD: Anti-inflammatory activity of carvacrol
protects the heart from lipopolysaccharide-induced cardiac
dysfunction by inhibiting pyroptosis via NLRP3/caspase1/gasdermin D
signaling axis. Life Sci. 324:1217432023. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Wu T, Ma W, Lu W, Huangshen Z, Chen S,
Yang Q, Li C, Li Z, Li N, Feng X, et al: Vaccarin alleviates
cisplatin-induced acute kidney injury via decreasing NOX4-derived
ROS. Heliyon. 9:e212312023. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Zhu X, Meng X, Du X, Zhao C, Ma X, Wen Y,
Zhang S, Hou B, Cai W, Du B, et al: Vaccarin suppresses diabetic
nephropathy through inhibiting the EGFR/ERK1/2 signaling pathway.
Acta Biochim Biophys Sin (Shanghai). 56:1860–1874. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Fan Q, Liu D, Chu C, Wang Y, Liu M, Liu Y,
Huang Y, Zhang J and Wen J: Vaccarin alleviates renal
ischemia-reperfusion injury by inhibiting inflammation and
ferroptosis. Int Immunopharmacol. 153:1144632025. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Zhu XX, Meng XY, Zhang AY, Zhao CY, Chang
C, Chen TX, Huang YB, Xu JP, Fu X, Cai WW, et al: Vaccarin
alleviates septic cardiomyopathy by potentiating NLRP3
palmitoylation and inactivation. Phytomedicine. 131:1557712024.
View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Liao R, Sun ZC, Wang L, Xian C, Lin R,
Zhuo G, Wang H, Fang Y, Liu Y, Yang R, et al: Inhalable and
bioactive lipid-nanomedicine based on bergapten for targeted acute
lung injury therapy via orchestrating macrophage polarization.
Bioact Mater. 43:406–422. 2024.PubMed/NCBI
|
|
152
|
Jiang Y, Nguyen TV, Jin J, Yu ZN, Song CH
and Chai OH: Bergapten ameliorates combined allergic rhinitis and
asthma syndrome after PM2.5 exposure by balancing Treg/Th17
expression and suppressing STAT3 and MAPK activation in a mouse
model. Biomed Pharmacother. 164:1149592023. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Zhu S, Cheng L, Chen T, Liu X, Zhang C,
Aji A, Guo W, Zhu J, Chu Y, Guo D and Li F: Bergapten ameliorates
psoriatic skin lesions and IL-17A-induced activation of the NF-κB
signaling pathway via the downregulation of CYP1B1. Phytother Res.
39:661–675. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Luo T, Jia X, Feng WD, Wang JY, Xie F,
Kong LD, Wang XJ, Lian R, Liu X, Chu YJ, et al: Bergapten inhibits
NLRP3 inflammasome activation and pyroptosis via promoting
mitophagy. Acta Pharmacol Sin. 44:1867–1878. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Bai D, Du J, Bu X, Cao W, Sun T, Zhao J,
Zhao Y and Lu N: ALDOA maintains NLRP3 inflammasome activation by
controlling AMPK activation. Autophagy. 18:1673–1693. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Honda TSB, Ku J and Anders HJ: Cell
type-specific roles of NLRP3, inflammasome-dependent and
-independent, in host defense, sterile necroinflammation, tissue
repair, and fibrosis. Front Immunol. 14:12142892023. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Yu Y, Yu S, Lu Z, Qiang L, Zhong Y, Ge P,
Lei Z, Qiu C, Fang Y, Zhang X, et al: Pathogenic phosphorylation of
linear ubiquitin machinery causes inflammasome sensor degradation.
Cell Rep. 44:1162862025. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Liang S, Zhou J, Cao C, Liu Y, Ming S, Liu
X, Shang Y, Lao J, Peng Q, Yang J and Wu M: GITR exacerbates
lysophosphatidylcholine-induced macrophage pyroptosis in sepsis via
posttranslational regulation of NLRP3. Cell Mol Immunol.
21:674–688. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Cui LG, Zhai MM, Yin JJ, Wang ZM, Wang SH,
Zhou YJ, Li PP, Wang Y, Xia L, Wang P, et al: Targeting the
ALKBH5-NLRP3 positive feedback loop alleviates cardiomyocyte
pyroptosis after myocardial infarction. Eur J Pharmacol.
989:1772472025. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Chen L, Zhang W, Chen H, Zhang Y, Guo B,
Yang L, Yin C, Zuo Q, Ren L, Bai L, et al: HDAC3 activates
endothelial NLRP3 inflammasome and promotes atherosclerosis via
inhibiting the acetylation of specificity protein 1. Cell Death
Differ. Nov 26–2025.(Epub ahead of print). View Article : Google Scholar
|
|
161
|
Liu S, Wu Z, Su Y and Qiu F: Successful
treatment of sepsis-induced cardiomyopathy with 36 h refractory
ventricular fibrillation: A case report. Heliyon. 10:e350842024.
View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Borkowski P, Borkowski M, Borkowska N,
Modak V, Nazarenko N, Mangeshkar S, Osabutey A, Maliha M, Chowdhury
I, Batikyan A, et al: The Complexities of sepsis-induced
cardiomyopathy: A clinical case and review of inflammatory pathways
and potential therapeutic targets. Cureus. 16:e751732024.PubMed/NCBI
|
|
163
|
Silva EE, Skon-Hegg C, Badovinac VP and
Griffith TS: The calm after the storm: Implications of sepsis
immunoparalysis on host immunity. J Immunol. 211:711–719. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Yu X, Song Y, Dong T, Ouyang W, Shao L,
Quan C, Lee KE, Tan T, Tsung A, Kurabayashi K, et al: Loss of PADI2
and PADI4 ameliorates sepsis-induced acute lung injury by
suppressing NLRP3+ macrophages. JCI Insight. 9:e1816862024.
View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Evans L, Rhodes A, Alhazzani W, Antonelli
M, Coopersmith CM, French C, Machado FR, Mcintyre L, Ostermann M,
Prescott HC, et al: Surviving sepsis campaign: International
guidelines for management of sepsis and septic shock 2021.
Intensive Care Med. 47:1181–1247. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Duan Y, Li Q, Wu J, Zhou C, Liu X, Yue J,
Chen X, Liu J, Zhang Q, Zhang Y and Zhang L: A detrimental role of
endothelial S1PR2 in cardiac ischemia-reperfusion injury via
modulating mitochondrial dysfunction, NLRP3 inflammasome
activation, and pyroptosis. Redox Biol. 75:1032442024. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Liu S, Tan M, Cai J, Li C, Yang M, Sun X
and He B: Ribosome-targeting antibiotic control NLRP3-mediated
inflammation by inhibiting mitochondrial DNA synthesis. Free Radic
Biol Med. 210:75–84. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Licini C, Morroni G, Lucarini G, Vitto
VAM, Orlando F, Missiroli S, D'Achille G, Perrone M, Spadoni T,
Graciotti L, et al: ER-mitochondria association negatively affects
wound healing by regulating NLRP3 activation. Cell Death Dis.
15:4072024. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Zhao PY, Yao RQ, Ren C, Li SY, Li YX, Zhu
SY, Yao YM and Du XH: De ritis ratio as a significant prognostic
factor in patients with sepsis: A retrospective analysis. J Surg
Res. 264:375–385. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Vande Walle L and Lamkanfi M: Drugging the
NLRP3 inflammasome: From signalling mechanisms to therapeutic
targets. Nat Rev Drug Discov. 23:43–66. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Tang F, Kunder R, Chu T, Hains A, Nguyen
A, McBride JM, Zhong Y, Santagostino S, Wilson M, Trenchak A, et
al: First-in-human phase 1 trial evaluating safety,
pharmacokinetics, and pharmacodynamics of NLRP3 inflammasome
inhibitor, GDC-2394, in healthy volunteers. Clin Transl Sci.
16:1653–1666. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Ridker PM, MacFadyen JG, Thuren T, Everett
BM, Libby P and Glynn RJ; CANTOS Trial Group, : Effect of
interleukin-1β inhibition with canakinumab on incident lung cancer
in patients with atherosclerosis: exploratory results from a
randomised, double-blind, placebo-controlled trial. Lancet.
390:1833–1842. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Saresella M, Zoia CP, La Rosa F, Bazzini
C, Sala G, Grassenis E, Marventano I, Hernis A, Piancone F, Conti
E, et al: Glibenclamide-loaded engineered nanovectors (GNVs)
modulate autophagy and NLRP3-inflammasome activation.
Pharmaceuticals (Basel). 16:17252023. View Article : Google Scholar : PubMed/NCBI
|
